Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 5/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.58 |
| ▸ | AURKA | O14965 | 10/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5801915 | 0.84 | TTK (0.60) | TTKMAPK8AURKAAURKBMAP2K7 | |
| SCHEMBL8446250 | 0.82 | AURKA (0.69) | TTKMAPK8AURKAAURKBMAP2K7 | |
| SCHEMBL5381465 | 0.81 | TTK (0.58) | TTKMAPK8AURKAAURKBMAP2K7 | |
| SCHEMBL29773342 | 0.78 | PARP1 (0.69) | TTKMAPK8AURKAPARP1LMNA | |
| SCHEMBL6786177 | 0.78 | PARP1 (0.69) | TTKMAPK8AURKAPARP1LMNA | |
| SCHEMBL8449528 | 0.76 | MAPK1 (0.53) | TTKMAPK8AURKAAURKBMAP2K7 | |
| SCHEMBL5802293 | 0.74 | TTK (0.52) | TTKMAPK8AURKAAURKBMAP2K7 | |
| SCHEMBL5803505 | 0.73 | MAP2K4 (0.53) | TTKMAPK8AURKAAURKBMAP2K7 | |
| Hydrochloric Acid SCHEMBL5377781 | 0.73 | TTK (0.51) | TTKMAPK8AURKAAURKBMAP2K7 | |
| Hydrochloric Acid SCHEMBL5382200 | 0.73 | TTK (0.51) | TTKMAPK8AURKAAURKBMAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | TTK 1198/4885MAPK8 26/4885AURKA 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.